HealthcareNUCLIDIUM Announces First Patient Imaged in Phase 1 Study Evaluating 61Cu-based Radiotracer in Patients with PSMA-positive Prostate Cancer
NUCLIDIUM today announced that the first patient has been successfully imaged in a phase 1 clinical trial evaluating the company’s radiotracer candidate as a safe and accurate diagnostic and disease-staging imaging agent in prostate cancer patients. 61Cu-NuriProTM (61Cu-NODAGA-PSMA I&T) is the diagnostic component of NUCLIDIUM’s NuriProTM program, binding specifically to Prostate Specific Membrane Antigen (PSMA). PSMA has evolved as an established biomarker for the diagnosis, staging, and treatment of patients suffering from certain types of prostate cancer.1,2,3,4 61Cu-NuriPro is the...